NASDAQ
No price data available for this timeframe.
Seres Therapeutics, Inc. (MCRB) has a price/sales ratio of 167.07x as of Friday, May 22, 2026. This represents a 12579.17% increase compared to its 12-month average of 1.32x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.